Browsing by Author "Schmid, Peter"
Now showing items 1-6 of 6
-
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Sablin, Marie-Paule; Bergh, Jonas; Im, Seock-Ah; Lu, Yen-Shen; Martínez, Noelia; Cortés Castan, Javier; Schmid, Peter (BMC, 2021-01-15) -
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
Bruzas, Simona; Gluz, Oleg; Harbeck, Nadia; Cortés Castan, Javier; Blohmer, Jens-Uwe; Schmid, Peter (Springer Nature, 2022-03-29) -
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Vahdat, Linda T.; Forero-Torres, Andres; Blackwell, Kimberly; Telli, Melinda L.; Melisko, Michelle; Cortés Castan, Javier; Schmid, Peter (Nature Research, 2021-05-20) -
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Tarantino, Paolo; Corti, Chiara; Cortés Castan, Javier; Mittendorf, Elizabeth; Schmid, Peter; Rugo, Hope (Nature Research, 2022-02-18) -
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy
Reinisch, Mattea; Bruzas, Simona; Gluz, Oleg; Ataseven, Beyhan; Schmid, Peter; Cortes, Javier (Wiley, 2023-06) -
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Bardia, Aditya; Marmé, Frederik; Cortés Castan, Javier; Loirat, Delphine; Gómez Pardo, Patricia; Schmid, Peter; Rugo, Hope (American Society of Clinical Oncology, 2022-10-10)